Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 18/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6075861 | 0.80 | CRHR1 (0.81) | CRHR1 | |
| SCHEMBL5409344 | 0.79 | CRHR1 (0.68) | CRHR1 | |
| SCHEMBL5409307 | 0.76 | CRHR1 (0.56) | CRHR1 | |
| SCHEMBL7216022 | 0.75 | CRHR1 (0.43) | CRHR1KDM4EMEN1ALDH1A1POLB | |
| SCHEMBL5412960 | 0.72 | CRHR1 (0.74) | CRHR1 | |
| SCHEMBL5423381 | 0.69 | CRHR1 (0.67) | CRHR1 | |
| SCHEMBL5419404 | 0.68 | CRHR1 (0.59) | CRHR1 | |
| SCHEMBL5420383 | 0.68 | CRHR1 (0.68) | CRHR1 | |
| SCHEMBL5415539 | 0.68 | CRHR1 (0.68) | CRHR1 | |
| SCHEMBL5419644 | 0.68 | CRHR1 (0.74) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-6995161-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050215559-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885KDM4E 3651/4885MEN1 2942/4885 |
| US-20050215559-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885KDM4E 3651/4885MEN1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.